InsiderTrades.com logo

JUNS Insider Trading

Insider Ownership Percentage: 50.80%
Insider Buying (Last 12 Months): $2,626.50
Insider Selling (Last 12 Months): $0.00

Jupiter Neurosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Jupiter Neurosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Jupiter Neurosciences Share Price & Price History

Current Price: $0.38
Price Change: ▲ Price Increase of +0.0026 (0.70%)
As of 04/9/2026 01:33 PM ET

This chart shows the closing price history over time for JUNS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Jupiter Neurosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/1/2025Alison D SilvaInsiderBuy750$1.03$772.50112,777View SEC Filing Icon  
6/30/2025Alison D SilvaInsiderBuy950$1.03$978.50112,027View SEC Filing Icon  
6/27/2025Alison D SilvaInsiderBuy850$1.03$875.50111,077View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Jupiter Neurosciences (NASDAQ:JUNS)

Jupiter Neurosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/10/2026Yorkville Advisors Global LP131,909$0.14M0.1%N/A0.383%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC132,641$0.14M0.0%+27.8%0.385%Search for SEC Filing on Google Icon
2/9/2026Allen Capital Group LLC30,000$31K0.0%N/A0.087%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Jupiter Neurosciences logo
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Read More on Jupiter Neurosciences

Today's Range

Now: $0.38
Low: $0.37
High: $0.40

50 Day Range

MA: N/A

52 Week Range

Now: $0.38
Low: $0.31
High: $3.33

Volume

49,889 shs

Average Volume

300,589 shs

Market Capitalization

$13.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.8

Who are the company insiders with the largest holdings of Jupiter Neurosciences?

Jupiter Neurosciences' top insider investors include:
  1. Alison D Silva (Insider)
Learn More about top insider investors at Jupiter Neurosciences.